Access Insights Conference 2026 Surges Toward Sellout as Biopharma Leaders Race to Secure Seats
Registration is filling fast for biopharma's only conference dedicated to the full spectrum of drug commercialization, taking place October 19–21 at the Mayflower Hotel in Washington, D.C.
PHILADELPHIA, Aug. 10, 2026 /PRNewswire/ -- IntegriChain, the leading provider of pharma revenue optimization technology and insights, today issued a call to action for market access, finance, and commercial leaders across the biopharma industry: seats for Access Insights Conference 2026 are now more than 50% claimed with less than 90 days remaining before the event opens. Demand has grown so quickly that registration for Access Insights 2025 sold out- a first in the conference's history.
Hosted by IntegriChain, Access Insights is the only conference dedicated to the full spectrum of biopharma commercialization, spanning regulatory policy, pricing strategy, and operational execution. Building on 2025's record-breaking attendance, this year's event brings together commercial, financial, and operational executives from pharmaceutical manufacturers navigating a landscape defined by policy volatility, pricing pressure, and rising launch stakes.
"We saw record attendance last year, and the response to 2026 has exceeded that pace," said Josh Halpern, CEO of IntegriChain. "Manufacturers are telling us the same thing: they need a room where policy, pricing, and operations are discussed together, not in silos. That's what Access Insights delivers."
Why Attendees Are Registering Now
Access Insights 2026 features expert-led sessions from industry strategists, operators, finance leaders, and technologists, with content tailored to a manufacturer's size, portfolio mix, and commercialization model. Attendees leave with a clear roadmap for navigating the next era of commercialization from strategic pre-launch planning to the operational execution that optimizes both patient access and net revenue.
"We intentionally cap the attendance at this conference to ensure quality over quantity, " said Bill Roth, SVP of Consulting & Advisory at IntegriChain. "When we sell out, we sell out and demand has been increasing year over year as word has gotten out about what our attendees learn here."
Access Insights 2026 is made possible with the support of leading commercialization and patient access organizations, including GiftHealth as the exclusive Titanium Sponsor and PHIL, Medfuse, Courier Health, and BioCareSD as Gold Sponsors.
Register Today
Pharmaceutical manufacturers interested in attending Access Insights Conference 2026 are encouraged to register immediately at Access Insights to secure their seat before the conference reaches capacity.
About IntegriChain
IntegriChain delivers biopharma's only comprehensive data-driven commercialization platform from strategy to operational execution connecting the commercial, financial, and operational dimensions of drug access and profitability. Our ICyte® platform integrates technology, data, consulting, and managed services to unify critical workflows replacing manual processes with integrated analytics and precision controls.
Biopharma relies on IntegriChain to optimize patient access and net revenue performance, reduce leakage, and strengthen compliance, ensuring every life-changing therapy reaches patients with speed, affordability, and sustainability. Backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in healthcare and technology. IntegriChain is headquartered in Philadelphia, PA, with a location in Pune, India. For more information, visit www.integrichain.com or follow us on LinkedIn.
Media Contact
Brandy Jensen, Senior Director, Marketing
IntegriChain
[email protected]
SOURCE IntegriChain, Inc.
Share this article